Phase-II Trial of Rebeccamycin Analog, a Dual Topoisomerase-I and -II Inhibitor, in Relapsed “Sensitive” Small Cell Lung Cancer  by Schwandt, Anita et al.
751Journal of Thoracic Oncology  •  Volume 7, Number 4, April 2012
BRIEF rEPoRT
Abstract: Relapsed small cell lung cancer (SCLC) carries a poor 
prognosis. Topoisomerase I and II inhibitors and DNA-damaging 
agents are considered among the most active agents against SCLC. 
Rebeccamycin analog (RA, Becatecarin) is an antitumor antibiotic 
with inhibitory activity against both topoisomerase I and II, and 
DNA-intercalating properties. We performed a phase-II trial of RA 
in relapsed, sensitive SCLC with the primary end point of response 
rate. Patients with previously treated SCLC who relapsed more than 
60 days after the completion of first-line chemotherapy were treated 
with RA-administered intravenously at a dose of 140 mg/m2 on days 
1 to 5 of 21-day cycles for a maximum of six cycles. Eligibility 
included Eastern Cooperative oncology Group performance status 0 
to 2 and adequate organ function. A two-stage design was employed. 
Twenty evaluable patients were enrolled. Median age was 61 years. 
Two patients (10%) had a partial response and six had stable disease. 
The clinical benefit rate was 40% (95% confidence interval [CI], 
23–64%). The median progression-free survival was 2 months (95% 
CI, 1.2–5.2 months). The median survival was 6.7 months (95% CI, 
3.3–8.0 months). No treatment-related deaths occurred. Grade-4 
neutropenia and thrombocytopenia occurred in 23% and 14% of the 
patients, respectively. In conclusion, RA has single-agent activity in 
relapsed, sensitive SCLC with manageable toxicities but is unlikely to 
provide any superiority compared to existing agents for this disease.
(J Thorac Oncol. 2012;7: 751–754)
Rebeccamycin, isolated from the actinomycete strain Saccharothrix aerocolonigenes, is an antibiotic that has 
antitumor properties and poor water solubility. It acts via a 
variety of mechanisms, including DNA intercalation, inducing 
both single- and double-stranded DNA breaks.1–3 It also acts 
as an inhibitor of both topoisomerases I and II.4 A glycosyl-
dichloroindolocarbazole analog of rebeccamycin (rebeccamy-
cin analog [RA], NSC 655649, Becatecarin), has improved 
water solublity.5 Mechanistic studies showed that RA is an 
intercalating agent that inhibits topoisomerase-II DNA strand 
passing function without stabilization of the cleavable com-
plex intermediate in a manner different from etoposide. The 
biethylamine group allows the RA to intercalate into the 
minor groove of poly (deoxyadenylate-deoxythmidylic acid) 
regions of DNA similar to the binding sites of doxorubicin. 
RA was not cross-resistant with VP-16 in the A549 (VP)29 
or HCT116(VP) 35 tumor cell lines, which were resistant by 
virtue of low topoisomerase-II content. It is not a p-glycopro-
tein substrate, and preclinical studies demonstrated activity 
against a variety of xenograft models. Several phase-I trials 
of a single infusion of RA in patients with solid tumors have 
been completed, including a once-every-3-weeks schedule 
and a five-times-daily schedule every 21 days.6–8 Based on 
higher systemic exposure, more prolonged plasma levels to 
inhibit target enzymes, preclinical superiority of repetitive 
dosing schedule, and greater observed antitumor activity dur-
ing phase-I trials the five-times-daily schedule was chosen for 
further development.
There is a great need for novel therapies for small cell 
lung cancer (SCLC). The attraction of the current agent under 
study is its triple mechanism of action including DNA dam-
age and topoisomerase-I and -II inhibition. We thus set out to 
perform a two-stage phase-II trial to determine the activity of 
this agent in relapsed “sensitive” SCLC. The primary objec-
tive was to determine the response rate (RR).
PATIENTS AND METHODS
Patients with SCLC were required to have had prior 
chemotherapy (prior radiation allowed). only patients with 
“sensitive” recurrence, defined by recurrence 60 days or more 
after completion of the first-line chemotherapy, were eligible. 
The protocol and consent form were approved by the institu-
tional review boards of the participating institutions, and all 
patients provided written informed consent. Eligibility criteria 
included: measurable disease, age older than 18 years, Eastern 
Cooperative oncology Group performance status of 2 or 
lesser, adequate renal function as defined by a creatinine less 
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than 2 mg/dl or a creatinine clearance of 60 ml/min/1.73 m2 
or more, and adequate hepatic function (serum bilirubin ≤ 1.5 
mg/dl and aspartate transaminase/alanine aminotransferase < 
2.5 × institutional upper limit of normal, or < 5 × upper limit 
of normal if the liver is involved by tumor; absolute neutro-
phil count ≥ 1500/μl; platelets ≥ 100,000/μl; and hemoglo-
bin ≥ 9.0 g/dl). Patients with brain metastasis were eligible 
if they had stable brain disease and were no longer receiving 
irradiation and steroids. RA was given at a dose of 140 mg/
m2 over 1 hour on a five-times-daily schedule repeated every 3 
weeks. Because of prior high incidence of infusion-site phle-
bitis, RA was infused through a central line. Tumor measure-
ments were made every two cycles. Response and progression 
were evaluated using Response Evaluation Criteria in Solid 
Tumors criteria. Treatment was continued until one of the fol-
lowing criteria occurred: patient has completed six cycles of 
treatment, patient was deemed to have disease progression, 
intercurrent illness occurred that prevented further adminis-
tration of treatment, unacceptable adverse event, or patient 
withdrawal of consent from the study.
Dose delays were allowed for laboratory values to return 
to baseline. A maximum delay of 2 weeks was accepted. Dose 
modifications of 25% were required for grade-4 hematologic 
and grade-3 nonhematologic toxicity felt by the investigator 
to be RA-related or if the cycle was delayed for more than 
1 week. A maximum of two dose reductions were allowed. 
Granulocyte-colony stimulating factor (G-CSF) support was 
allowed per treating physician’s discretion.
A two-stage design was used so that the study would 
be terminated after 20 patients if there were only one or no 
objective responses, would continue to accrue an additional 
15 patients, and the drug would be deemed worthwhile if 
8 patients or more of 35 responded to treatment. In this design, 
a true RR of 30% or more is of interest whereas a RR of less 
than 10% is not. This stopping rule has a 90% probability 
( = 0.10) of calling the drug worthwhile when it is and a 5% 
probability (a = 0.05) of calling the drug worthwhile falsely 
when it is not. Secondary end points included progression-
free survival (PFS) and overall survival (oS).
RESULTS
A total of 21 eligible patients were enrolled between 
November 2004 and November 2007. of these, 20 patients 
were evaluable as one patient had clinical deterioration after 
consent but before the first dose of drug administration. 
Baseline characteristics of the study population are listed in 
Table 1. A total of 59 cycles were administered in this trial 
with a median of 2.9 (range, 1–6). The majority of the patients 
(54%) were withdrawn from the study because of disease pro-
gression and/or death secondary to complications of primary 
disease. Four patients (20%) received the preplanned maxi-
mum of six cycles. The median duration of treatment was 1.56 
months (range, 0.36–5.15 months). No patient was removed 
from study because of treatment-related adverse events.
The treatment-related adverse events are listed in Table 2. 
The most common reasons for treatment delays or dose modi-
fication were myelosuppression. Grade 3/4 neutropenia and 
thrombocytopenia occurred in 37% and 33% of patients, 
respectively. However, the neutropenia was generally short-
lived with only two episodes of febrile neutropenia. G-CSF 
was used in 30% of the patients (none during cycle 1). No 
episode of clinical bleeding was observed with the throm-
bocytopenia. In terms of nonhematological toxicity, fatigue, 
nausea/vomiting, anorexia, and dyspnea were among the most 
common treatment-related clinical toxicities. one patient had 
grade-4 cardiac symptoms with elevated troponin.




 Male 10 (50%)
 Female 10 (50%)
Median age (yrs) 61 (range 45–72)
Race
 White 16 (80%)
 African American 4 (20%)
ECoG PS
 0 5 (25%)
 1 10 (50%)
 2 5 (25%)
Prior therapy
 Chemotherapy 20 (100%)
 Radiation 8 (40%)
ECoG PS, Eastern Cooperative oncology Group performance status.
TABLE 2. Drug-Related Adverse Events Per NCI Version 3.0 
in All Cycles (Patients = 20, Total Cycles = 59)
Adverse Event Toxicity Grade (%)
1–2 3 4 Total
Hematological
 Neutropenia 4 14 23 42
 Febrile Neutropenia 0 4 0
 Thrombocytopenia 14 19 14 47
 Anemia 37 9 4 52
Nonhematological
 Fatigue 52 4 0 56
 Weight loss 13 0 0 13
 Anorexia 37 0 0 37
 Taste disturbance 18 0 0 18
 Nausea 51 0 4 55
 Vomiting 23 0 4 27
 Constipation 23 0 0 23
 Diarrhea 23 4 0 27
 Dyspnea 4 19 0 23
 Rash/desquamation 14 0 0 14
 Mood alteration, anxiety, agitation 14 0 0 14
 Infection without neutropenia 4 4 0 8
 Cardiac troponin 0 0 4 4
Data presented as percent occurrence with highest grade in each patient. only 
toxicities listed as at least possibly related to study drug are listed.
NCI, National Cancer Institute.
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Two patients (10%) had partial response (95% confi-
dence interval [CI] (3%, 30%). Six patients (30%) had stable 
disease for a clinical benefit rate (= PR + stable disease) of 
40% (95% CI 22–61%). Although the prespecified criterion for 
proceeding to the second stage of accrual was met, because of 
inadequate drug supply further accrual was not pursued. The 
median PFS was 2 months (95% CI 1.21, 5.15). The 6-month 
PFS rate was 20% with 95% CI (6.2%, 39.3%). Median sur-
vival was 6.7 months (95% CI 3.3–8.0 months) (Fig. 1) and 
1-year survival was 10% (95% CI, 1.7%, 27.2%).
DISCUSSION
SCLC remains a disease that has had little therapeu-
tic advancement over the past three decades. Specifically, in 
the salvage setting topotecan remains the only approved drug 
for this setting with a RR of 7% and median survival of 25.9 
weeks (6–7 months) in patients who are considered to have so-
called sensitive relapse i.e., progression 60 days or more after 
completion of the first-line treatment.9,10 Recently a random-
ized phase-III trial compared amrubicin, a topoisomerase-II 
inhibitor to topotecan and failed to show any superiority to 
standard treatment.11 Topoisomerase-I inhibitors (such as iri-
notecan and topotecan) as well as topoisomerase-II inhibi-
tors (such as etoposide and doxorubicin) are the mainstay for 
treatment of this disease.12,13 It was thus highly attractive to 
evaluate RA in this disease given its dual topoisomerase-I 
and -II inhibition. In addition, preclinical models had suggested 
that RA may have anticancer effects in etoposide-resistant cell 
lines. The objective RR for RA in this study was 10% in the 
first 20 patients. Although our trial met its prespecified end 
point for pursuing the second stage of accrual, because of stra-
tegic decisions by the pharmaceutical supplier and the fact that 
RA was unlikely to provide any superiority to existing agents 
we did not pursue further accrual. In the first 20 patients the 
RR of 10%, 6-month PFS of 20% and overall survival of 6.7 
months is comparable to topotecan in the same patient popula-
tion. The toxicities of RA in this patient population mimic RA 
toxicities in other phase-II studies of this agent, predominately 
myelosuppression, with no additional safety signals.
Thus the strategy of dual simultaneous topoisomerase-I 
and -II inhibition may not be the right approach in this disease. 
More attention has been paid to sequential topoisomerase-I 
and -II inhibition, with initial exposure to topoisomerase I 
resulting in an upregulation of topoisomerase II at which time 
exposure to the topoisomerase-II inhibitor will cause a signifi-
cant increase in cell death. We have demonstrated the failure of 
this approach in non–small cell lung cancer.14 Conversely, this 
approach is the subject of the Eastern Cooperative oncology 
Group trial E5501, for which the results have not yet been 
published. Further trials of RA in SCLC is unlikely to be pur-
sued given the current status of agents in development for this 
disease.
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